Congenital Adrenal Hyperplasia
Neurocrine Biosciences completed a Phase II study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of crinecerfont in adult patients with classic congenital adrenal hyperplasia (CAH). The final results from this open-label, multiple-dose, dose-escalation study were reported in June 2020. Neurocrine Biosciences plans to initiate a single, global registrational study of crinecerfont in adult patients with classic CAH in the second half of 2020.
Neurocrine Biosciences is conducting a Phase II, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of crinecerfont in pediatric female and male patients (14 to 17 years of age) with classic 21-hydroxylase deficiency CAH. For more information on this Phase II study of crinecerfont in pediatric patients with CAH, please visit CAHlibratePediatricStudy.com or clinicaltrials.gov.